It's a startling moment, when what seems like a distant problem hits close to home. In a one-stoplight town in Eastern Kentucky, my neighbor's alarming descriptions of prescription drug abuse were as distantly vague to me as someone attempting to explain what New York City felt like; it just didn't compute. Up until I encountered it firsthand, I'd heard gossip about locals getting addicted to pain pills but it seemed like an apparition, something blown out of proportion in a hairdresser's hyperbole.
Most Recent Posts
As a pretty healthy person, the only time I really struggle to breathe is after a long grueling run. But for individuals with asthma it can be a common occurrence. Today, more than 24 million American adults and children suffer from asthma, with that number continuing to grow, according to the CDC. Asthma is a narrowing of the airways to the lungs caused by inflammation in the air passages, resulting from both genetic and environmental influences. Symptoms can include difficulty breathing, wheezing, and coughing tightness in the chest.
Today, we have a guest post from Eileen Cannon, Executive Director for the PhRMA Foundation. Below, Eileen discusses the challenges and the progress made by the PhRMA Foundation fellows in regard to rare disease research.
We have always espoused the view that good adherence to prescription medicines can improve health outcomes, help control health care costs, and improve patients' lives. Here at PhRMA, we pay close attention to the literature that supports this belief.
It's no secret that encouraging adherence among patients can be a challenge. We know that patients who are more compliant regarding their prescribed treatment regimen tend to have better health outcomes. However, the problem has been finding a way to effectively encourage compliance.
Although we are recognizing today as Rare Disease Day, for some people, every day is rare disease day. Ask Sigma-Tau what's the difference between their commitment to fighting a disease affecting 300 and 3,000,000, and they'll tell you: nothing. Below, we sat down with Sigma-Tau's Gregg Lapointe to discuss this important issue:
Today is international Rare Disease Day, an event established to support the millions of people around the world affected by rare diseases. This year's focus is on solidarity and the need for collaboration in the field.
Today, we have a guest post from Jack Cox, Senior Director of Media Relations for Sanofi US. Below, Jack discusses how the times are changing with regard to how pharmaceutical companies communicate online.
There were a couple of recent posts on vaccines and vaccination worth a look. One focuses on the future and the prospects for the development of a "universal" vaccine to control the flu and reduce the potential for pandemics. The second points out that unvaccinated children still pose a potential threat to vaccinated children.
An old saying, "A penny for your thoughts?" comes to mind as the Administration continues its call to action to help spur innovation in America. As part of this effort, the federal government is awarding prizes to creative thinkers and problem solvers who come up with inventions that help address the many challenges we face as a society.
Prevention is important in healthcare, and just how important is becoming clearer all the time. Today, in the New York Times there was a story underscoring how important preventative medicine is - and how successful. The Times reported on a newly released New England Journal of Medicine study - subscription only - of the long-term benefits of colonoscopies.
Coming to work at PhRMA a year and a half ago required a bit of a crash course in the incredibly complex and always evolving biopharmaceutical research sector.
Late Friday afternoon, PhRMA submitted our comments to the Centers for Medicare and Medicaid Services about the agency's proposed rule for implementation of the Physician Payment Sunshine provision of the Affordable Care Act.
To help keep Catalyst readers well-informed with the latest news, I want to bring to your attention that a fake cancer drug is circulating in the U.S. drug supply system. According to press reports, the maker of the drug is not yet aware of how the counterfeit medicine got in the supply and where it originated from.